The growth of the global topical pain relief market is thriving on the back of the increasing prevalence of musculoskeletal disorders, wherein increasing prevalence of osteoarthritis and autoimmune arthritis are the primary factors, which have positively impacted the market growth. The growing number of the elderly population, particularly in developed nations such as Japan, Germany, Italy, and the US has also created potential opportunities for the manufacturers to develop the products, which can effectively treat the disease. Furthermore, recent technological advancements pertaining to the development of transdermal patches for pain management has also created vast opportunities for the market to flourish. Additionally, increasing investments from leading pharmaceutical companies as well as government organizations for R&D activities have led to the development of new topical formulations for multiple chronic disorders ranging from pain relief in brain disorders such as Parkinson’s to chronic pruritis, which in turn have also contributed significantly to the expansion of global topical pain relief market.
The global topical pain relief market reached a value of USD 7699.34 million in the year 2019 and is expected to garner a value of USD 11133.17 million by the end of 2028 by registering a CAGR of 4.31% across the globe over the forecast period 2021-2028. Further, the worldwide market of topical pain relief is anticipated to achieve an absolute $ opportunity of USD 2844.56 million throughout the forecast period.
Growth Highlights based on Region during 2019-2028
The global topical pain relief market is segmented by regions into North America, Latin America, Europe, Asia Pacific and Middle East and Africa. Among these regions, the market of North America topical pain relief is driven by U.S. and Canada, where U.S. held the dominant market share of 78.44% in the year 2019. Growing incidences of arthritis in the region, increasing geriatric population, rising incidences of sport-related injuries, rising consumer awareness for topical pain relief products and growing utilization of topical pain relievers are some of the factors driving the growth of the topical pain relief market in North America. Additionally, the North America topical pain relief market, which held a share of 39.68% in the year 2019, is expected to expand by observing the growth rate of 1.29x over the forecast period, which in turn is estimated to have a positive effect on the demand for topical pain relievers in the long run.
Further, U.K., Germany, Italy and France are some of the prominent countries that are driving the growth of the Europe topical pain relief market, where U.K. accounted for the largest market share of 20.87% in the year 2019. Continuous advancements pertaining to the increased adoption of transdermal patches for chronic disorders, coupled with the increasing R&D investments by few major players are among the major factors expected to propel the growth of the topical pain relief market in Europe. CLICK TO DOWNLOAD SAMPLE REPORT
The study further incorporates Y-O-Y Growth, demand & supply and forecast future opportunity in North America (United States, Canada), Latin America (Brazil, Mexico, Argentina, Rest of LATAM), Europe (U.K., Germany, France, Italy, Spain, Hungary, BENELUX [Belgium, Netherlands, Luxembourg], NORDIC [Norway, Denmark, Sweden, Finland], Poland, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Indonesia, Taiwan, Hong Kong, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa).
Market Segmentation Synopsis
By Therapeutic Class
The global topical pain relief market has been segmented on the basis of therapeutic class into opioids and non-opioids. The non-opioids segment is further sub-divided into non-steroidal anti-inflammatory drugs, lidocaine and others. The non-steroidal anti-inflammatory drugs segment with 54.31% share in the year 2019, occupies the largest market of topical pain relievers across the globe. Additionally, the non-steroidal anti-inflammatory drugs segment is anticipated to cross USD 6747.0 million by the end of 2028 by registering a CAGR of 4.21% over the forecast period. Further, the lidocaine segment is estimated to grow with the highest CAGR of 4.49% over the forecast period.
Market Drivers and Challenges
As per the statistics of the American College of Rheumatology, osteoarthritis is the most common form of arthritis and it affects around 302 million people worldwide, every year.
Growing incidences of arthritis, particularly osteoarthritis across the world is a primary factor, which is anticipated to propel the market growth over the forecast period. Osteoarthritis is also a leading cause of disability among older adults, wherein the most affected appendicular joints are knees, hips, and joints. According to the Arthritis Foundation, arthritis in tandem with back pain is a leading cause of work disability in the US. It is also the most common cause, which requires rehabilitation and thus has the greatest impact on the healthcare system in the country. On the other hand, rising adoption of analgesics for instant pain relief is another major factor anticipated to drive the market growth over the forthcoming years. Topical pain relievers are available in multiple forms such as gels, ointments, creams, and sprays, which not only have lesser systemic side effects as compared to a similar oral dosage but can also be compounded and individualized in the right concentration as per the specific needs of the consumer. Additionally, the growing popularity of topical as well as transdermal creams and patches among the sportspersons, on account of its numerous advantages has directly impacted its increased adoption. Sports-related soft tissue injuries, such as strains, sprains, and contusions are extremely common. As per the statistics of Sandford Children’s Health, approximately 30 million children and teens in the US participate in some form of sports, wherein more than 3.5 million children experience some sort of physical injury. Such factors are anticipated to drive the growth of the global topical pain relief market.
Limited availability of topical pain relievers for neonates and pediatrics, as the use of topical anesthetics and analgesics in children generally requires a proper prescription, along with the concern for severe allergic reactions on the back of excessive and continuous use of topical gels and creams are some of the factors anticipated to impact negatively towards the growth of the global topical pain relief market.
Some of the affluent industry leaders in the global topical pain relief market are Reckitt Benckiser Group plc, Teikoku Pharma USA, Inc., Topical BioMedics, Inc., Sun Pharmaceutical Industries Ltd., AdvaCare Pharma®, Sanofi, Johnson & Johnson Services, Inc., Novartis AG, Pfizer Inc. and GlaxoSmithKline plc.
Increasing investments from leading pharmaceutical companies as well as government organizations for R&D activities, increasing elderly population are some of the major factors that are driving the growth of the market.
The market is anticipated to attain a CAGR of 4.31% over the forecast period, i.e. 2021-2028.
North America is anticipated to hold the dominating share in the market.
The market in Europe is anticipated to provide more business opportunities for growth over the years to come.
The major players in the global topical pain relief market are Reckitt Benckiser Group plc, Teikoku Pharma USA, Inc., Topical BioMedics, Inc., Sun Pharmaceutical Industries Ltd., AdvaCare Pharma®, Sanofi, Johnson & Johnson Services, Inc., Novartis AG, Pf
The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.
The market is majorly segmented by therapeutic class, formulation, distribution channel and by region.
The non-steroidal anti-inflammatory drugs segment, which is a sub-segment of the non-opioids segment under the therapeutic class segment, held a market share of 54.31% share in the year 2019 and is anticipated to display significant growth opportunity.
Growing concerns for the severe allergic reactions and the limited availability are some of the major factors anticipated to act as a barrier towards the growth of the global topical pain relief market.
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization